1. Scrip
  2. >>R&D
  3. >>Clinical Trials

AbbVie Next-Gen Combo Data Further Goal To Target Hard-To-Cure HCV Patients

 
• By Joseph Haas

Data from EXPEDITION-1 show a 99% SVR rate for HCV patients with compensated cirrhosis after 12 weeks of therapy. AbbVie also will present data at EASL on the utility of glecaprevir/pibrentasvir in CKD, post-liver or kidney transplant, HIV co-infected and treatment-failure patients.

Liver

With Viekira Pak missing sales expectations in hepatitis C, AbbVie Inc. has placed substantial hope on its next-generation combo glecaprevir/pibrentasvir with a special focus on difficult-to-treat HCV sub-populations. At the International Liver Congress, the Chicago-area pharma is presenting data demonstrating the fixed-dose combo can cure many HCV-infected patients with compensated cirrhosis without ribavirin add-on therapy.

On the opening day of the European Association for the Study of Liver Diseases meeting in Amsterdam, AbbVie reported that...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Boehringer Ingelheim Expects Two Key Approvals In Second Half Of 2025

 
• By Andrew McConaghie

The privately held German pharma firm is hoping to bring a new generation of pulmonary fibrosis and cancer drugs to market but their commercial success is not yet a certainty.

Memo Therapeutics Plans BK Virus Therapy Phase III Despite Trial Miss

 
• By Manas Mishra

Pointing to data that show a benefit in reducing viral load and the histological signs of the infection, Memo says its drug, potravitug, could become the first therapy to treat BK polyomavirus in kidney transplant recipients.

AZ Poised To Bring Self-Administered C5 Inhibitor To Market

 
• By Jessica Merrill

Gefurulimab will give AstraZeneca a new option to compete against Argenx’s Vyvgart Hytrulo, which is available subcutaneously.

Leo Looks To Grow In US After Hand Eczema Cream Approval

 
• By Kevin Grogan

The Danish medical dermatology specialist doubles boosts its sales force ahead of the launch of Anzupgo.

More from R&D

AZ Poised To Bring Self-Administered C5 Inhibitor To Market

 
• By Jessica Merrill

Gefurulimab will give AstraZeneca a new option to compete against Argenx’s Vyvgart Hytrulo, which is available subcutaneously.

Leo Looks To Grow In US After Hand Eczema Cream Approval

 
• By Kevin Grogan

The Danish medical dermatology specialist doubles boosts its sales force ahead of the launch of Anzupgo.

Obesity Beyond GLP-1s: Amylins – The Next Frontier

 
• By Aakash Babu

In this series of articles, we look at different mechanisms of actions beyond GLP-1s that could determine the obesity drug landscape in the coming years. First on our list – amylin receptor agonists, which analysts expect to grow into a $50bn market opportunity.